A Diabetes Outcomes Progression Trial (Completed)

ADOPT was a pragmatic, real-life, double-blind, randomised multicentre study which was evaluating specifically whether thiazolidinediones, with their different mode of action, can provide more durable glycaemic control than metformin or sulphonylureas. By utilising a monotherapy approach, in people with T2DM diagnosed for less than three years who are antihyperglycaemic agent naïve, ADOPT was designed to compare the relative efficacy of these three oral agents as judged primarily by the time to monotherapy failure. ADOPT will provide data on the effect of mechanistically differing treatment options on metabolic control, beta cell function, and markers of macrovascular disease risk in type 2 diabetes.